Clinical trials: Chikungunya Fever
Chikungunya Virus
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.
- Trial name
- NCT05072080
- Testing
- CHIKV VLP/adjuvant
- Where
- 47 sites in United States
- Volunteers
- 3,258 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Chikungunya Fever
The Pilot Study of Chikungunya Virus Infections in Southern Taiwan
This test is to be collected during the dengue outbreak samples, including samples back in the past and forward to close the case, investigating the prevalence of serum Chikungunya virus infection, and against those suspected…
- Trial name
- NCT02174341
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Arbovirus Infections
Spatial Repellents for Arbovirus Control
Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly.
- Trial name
- NCT03553277
- Testing
- transfluthrin
- Where
- Peru
- Volunteers
- 18,240 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Chikungunya Virus Infection
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control.
- Trial name
- NCT06106581
- Testing
- VLA1553 full dose, VLA1553 half dose, Control
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya
Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
This study has a Phase II with part A and part B and a Phase III with part C. This Adaptive seamless design will prospectively include planned modifications and incorporate both dose selection (parts A and B) and confirmation of…
- Trial name
- IVICHIK001 (NCT04566484)
- Testing
- BBV87 Chikungunya vaccine, Normal Saline
- Where
- 7 sites in Colombia, Costa Rica and 3 more
- Volunteers
- 3,210 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Chikungunya Virus Infection
Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
This is a cross-sectional serosurvey using household cluster sampling conducted before the VLA1553 pilot vaccination strategy will be implemented in about 10 municipalities in Brazil.
- Trial name
- NCT07163845
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 4 sites in Brazil
- Volunteers
- 5,354 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Arbovirus Infections
Spatial Repellents for Aedes-borne Virus Control in Sri Lanka
The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of a single SR product, in reducing DENV infection and active Aedes-borne virus (ABV) disease in human cohorts.
- Trial name
- AEGIS ABV (NCT05452447)
- Testing
- Transfluthrin
- Where
- 2 sites in Sri Lanka
- Volunteers
- 6,949 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Chikungunya Virus
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site…
- Trial name
- NCT07467707
- Testing
- CHIKV VLP vaccine
- Where
- 3 sites in Philippines, Thailand
- Volunteers
- 6,144 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Chikungunya
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
This was a prospective, randomized, double-blinded, multicenter, pivotal study evaluating the full dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control.
- Trial name
- NCT04650399
- Testing
- Active
- Where
- 10 sites in Brazil
- Volunteers
- 754 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Chikungunya Virus Infection
A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
VLA1553-322 is a multicenter, prospective, randomized, double-blind, phase 3 clinical trial evaluating VLA1553 in comparison to a comparator (Nimenrix®) for each stratum (age group).
- Trial name
- NCT07133178
- Testing
- VLA1553, Control
- Volunteers
- healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue, Vector Borne Diseases
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
Effective control of Aedes aegypti mosquitoes in breeding sites with high reproductive rates could have a major impact on reducing arbovirosis in endemic communities.
- Conditions
- Dengue, Vector Borne Diseases, Arbovirus Infections, Zika
- Trial name
- NCT06268691
- Testing
- Insecticide Coating INESFLY
- Where
- 2 sites in Colombia, Germany
- Volunteers
- 35,000 people, healthy volunteers welcome
- Sponsor
- Rocio Cardenas Sanchez
Chikungunya Virus
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to <12 years of age.
- Trial name
- NCT07003984
- Testing
- CHIKV VLP vaccine
- Where
- 15 sites in United States, Philippines and 1 more
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Dengue Fever
A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
This is a cluster randomized controlled trial (CRCT) to evaluate the efficacy of Wolbachia-infected A. aegypti mosquito releases in reducing the burden of ARBV infection in Brazil over four years.
- Trial name
- NCT04514107
- Testing
- Brazilian National Dengue Control Program, Wolbachia-infected Aedes aegypti
- Where
- Brazil
- Volunteers
- 5,757 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Virus Infection
Consequences of a Maternal-fetal Chikungunya Virus Infection
Chikungunya is an infectious disease caused by an alphavirus transmitted by the Aedes mosquitoes which has known a worldwide expansion since its re-emergence in 2004.
- Trial name
- CHIK13+ (NCT04909411)
- Testing
- OPHTHALMOLOGICAL ASSESSMENT, NEUROPSYCHOLOGICAL ASSESSMENT
- Where
- Reunion
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Healthy Adult, Healthy Adolescents
Evaluation of IXCHIQ® Vaccine Immunogenicity
The goal of this clinical trial is to evaluate the quality and duration of the immune response against chikungunya virus elicited by the IXCHIQ® vaccine in healthy adults and adolescents.
- Trial name
- IMUNO-CHIQ (NCT07846293)
- Testing
- IXCHIQ vaccine
- Where
- Brazil
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Mauro Martins Teixeira
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Dengue, Zika
Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At Scale
Mosquito-borne diseases cause suffering for hundreds of millions of people and claim more than 700,000 lives yearly. Diseases such as dengue, Zika, and chikungunya cause symptoms similar to malaria and are endemic in many parts…
- Conditions
- Dengue, Zika, Chikungunya
- Trial name
- NCT06595745
- Testing
- Wolbachia induced incompatible mating, Standard traditional chemical mosquito control
- Where
- Mexico
- Volunteers
- 15,243 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Chikungunya Virus Infection
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination
The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate…
- Trial name
- NCT06007183
- Testing
- CHIKV VLP vaccine booster
- Where
- 24 sites in United States
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Zika Virus, Pregnancy Related
ZIKAlliance Pregnant Women Cohort
The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations.
- Trial name
- ZIKAlliancePW (NCT03188731)
- Where
- 14 sites in Bolivia, Brazil and 5 more
- Volunteers
- 3,852 people, healthy volunteers welcome
- Sponsor
- University of Heidelberg Medical Center